Raphin1

• Description:

  Raphin1 is an orally bioavailable, selective inhibitor of the regulatory phosphatase PPP1R15B (R15B) . Raphin1 binds strongly to the R15B-PP1c holophosphatase (Kd=33 nM), and shows ~30-fold selective in binding R15B-PP1c over R15A-PP1c. Raphin1 crosses the blood-brain barrier, and reduces organismal and molecular deficits in a mouse model of a protein misfolding disease[1].

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Phosphatase

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  Neuroscience-Neurodegeneration

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/raphin1.html

• Purity:

  99.75

• Solubility:

  DMSO : 50 mg/mL (ultrasonic)

• Smiles:

  N=C(N/N=C/C1=CC=CC(Cl)=C1Cl)N

• Molecular Formula:

  C8H8Cl2N4

• Molecular Weight:

  231.08

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Krzyzosiak A, et al. Target-Based Discovery of an Inhibitor of the Regulatory Phosphatase PPP1R15B. Cell. 2018 Aug 23;174 (5) :1216-1228.e19.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Citation 01:

  Nat Commun. 2024 Aug 9;15 (1) :6810.|bioRxiv. 2024 Feb 5.|Nature. 2023 Sep;621 (7977) :188-195.

• CAS Number:

  [2022961-17-5]